Cenegermin

CHEMBL4297852 Phase 4 승인됨 Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A recombinant form of human nerve growth factor administered as eye drops to treat neurotrophic keratitis, a rare corneal disease caused by impaired nerve supply to the eye. By supporting corneal nerve regeneration and epithelial healing, it addresses the underlying pathology rather than just symptoms. It represents the first topical treatment specifically targeting the neurological cause of this condition.

치료 영역

작용 기전

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A recombinant form of human nerve growth factor administered as eye drops to treat neurotrophic keratitis, a rare corneal disease caused by impaired nerve supply to the eye. By supporting corneal nerve regeneration and epithelial healing, it addresses the underlying pathology rather than just symptoms. It represents the first topical treatment specifically targeting the neurological cause of this condition.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Cenegermin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297852. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.